<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946448</url>
  </required_header>
  <id_info>
    <org_study_id>S64746</org_study_id>
    <nct_id>NCT04946448</nct_id>
  </id_info>
  <brief_title>COmbinAtion Therapy of dieT With biologicalS for Crohn's Disease: the OATS Study</brief_title>
  <acronym>OATS</acronym>
  <official_title>COmbinAtion Therapy of dieT With biologicalS for Crohn's Disease: the OATS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised open label study, comparing the FIT diet with standard diet in&#xD;
      patients with Crohn's disease treated with biologic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steroid-free clinical and biochemical remission</measure>
    <time_frame>Month 6</time_frame>
    <description>Normalization of faecal calprotectin (&lt; 250 µg/g) and steroid-free clinical remission, defined as patient PRO2 ≤ 8 (average daily stool frequency ≤ 1.5 AND average daily abdominal pain score ≤ 1), at month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>≥ 30% decrease in average daily stool frequency and/or ≥ 30% decrease in average daily abdominal pain score and both not worse than baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>PRO2≤8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free clinical remission</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>PRO2≤8, no steroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>1 year</time_frame>
    <description>SES-CD &lt;2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic improvement</measure>
    <time_frame>1 year</time_frame>
    <description>drop in SES-CD with at least 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP improvement</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>50% or more improvement in CRP or CRP &lt;5 mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin improvement</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>50% or more improvement in faecal calprotectin or faecal calprotectin &lt;250 µg/g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants without nutritional deficiencies</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Absence of vitamin B12, vitamin D, folic acid, iron deficiencies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>30% or more improvement in IBD Disk energy score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>30% or more improvement in overall IBD Disk score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Diet, Healthy</condition>
  <arm_group>
    <arm_group_label>FIT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with biological treatment and the FIT diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients treated with biological treatment and the standard diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FIT diet</intervention_name>
    <description>Dietary intervention as add-on therapy to biologicals</description>
    <arm_group_label>FIT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18-80 years)&#xD;
&#xD;
          -  active inflammation of terminal ileum and/or colon with a Simple Endoscopic Score for&#xD;
             Crohn's Disease (SES-CD) greater than 5 (or greater than 3 for patients with isolated&#xD;
             ileitis),&#xD;
&#xD;
          -  patient reported outcome 2 (PRO2 - 7 day average daily stool frequency x 2 + 7 day&#xD;
             average daily abdominal pain score x 5) &gt; 8,&#xD;
&#xD;
          -  faecal calprotectin above 250 µg/g.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abcess,&#xD;
&#xD;
          -  Bowel resection within 6 months before enrolment,&#xD;
&#xD;
          -  Ostomy,&#xD;
&#xD;
          -  Short-bowel syndrome,&#xD;
&#xD;
          -  Clinically significant stricture that could require surgery,&#xD;
&#xD;
          -  Pregnant,&#xD;
&#xD;
          -  Lactating woman or desire to become pregnant during the study,&#xD;
&#xD;
          -  Unwilling or unable to follow the study diet.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>João PG Sabino, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>João PG Sabino, MD PhD</last_name>
    <phone>003216341770</phone>
    <email>joao.sabino@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isolde Aerden</last_name>
    <email>isolde.aerden@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João PG Sabino, MD PhD</last_name>
      <phone>003216341770</phone>
      <email>joao.sabino@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>João PG Sabino, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

